1228430-38-3

Upstream product

• 417726-36-4 (S)-1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridine-2-carboxylic acid 
• 1228430-37-2 (S)-1-tert-butyl 2-methyl 2,3-dihydropyridine-1,2(6H)-dicarboxylate 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 1228430-39-4 (2S)-2-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-1,2,3,6-tetrahydropyridine 
• 1228430-40-7 (2S)-2-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-1-[(4-methylphenyl)sulfonyl]-1,2,3,6-tetrahydropyridine 
• 1228430-41-8 (1R,4S,6R)-4-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-3-[(4-methylphenyl)sulfonyl]-3-azabicyclo[4.1.0]heptane 
• 1228430-55-4 (1R,4S,6R)-4-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)-3-azabicyclo[4.1.0]heptane 

Relevant academic research and scientific papers

AZABICYCLO [4.1.0] HEPT - 4 - YL DERIVATIVES AS HUMAN OREXIN RECEPTOR ANTAGONISTS

This invention relates to azabicyclo[4.1.0]hept-4-yl derivatives and their use as pharmaceuticals.

NOVEL COMPOUNDS

Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS

This invention relates to 3-azabicyclo[4.1.0] heptane derivatives (I) and their use as orexin receptor antagonists.